hotspot -WSS

hotspot

author：entertainment 2025-08-04 12:34:06 - browse：997

Adobe

The medical device industry is split on whether a proposed new Medicare reimbursement pathway will do anything to soothe their insurance coverage woes.

Device makers have long complained that the unclear, rocky road to payment kills innovative companies. So they were thrilled when the Trump administration proposed a rule that would have guaranteed four years of Medicare coverage of approved devices deemed “breakthroughs” by the Food and Drug Administration. They hoped private payers would follow suit. But in 2021, under a new administration and a push for more device scrutiny, the Centers for Medicare and Medicaid pulled back on the idea, promising a replacement that would streamline coverage for innovative devices while ensuring safe, high-quality care.

The pathway put forth last week, called Transitional Coverage for Emerging Technologies (TCET), is only a notice, not yet a rule that would grant CMS new powers. The program applies solely to devices that have earned a place in the FDA’s breakthrough device program, which was established to identify devices that the agency believed could provide “more effective” treatment or diagnosis of serious conditions than the current standard of care. But because those devices can be brought to market with less certainty in their benefits and risks than other products, experts said, the idea of automatic reimbursement was dicey.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Massive project maps cells in human brain in unprecedented detail

focus

WSS

PBM reforms clear House panel

CRISPR pioneers react to Casgevy, first gene

Akero's treatment for NASH falls short in cirrhosis study

Gain of function research would be limited under House proposal

Wellcome Trust names Røttingen as its new CEO

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

focus

hotspot

explore

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Childhood cancer progress stalls for Black, Hispanic kids: Report

State Dept. review finds Biden bears some blame for Afghanistan failures

In key trial, Verve's treatment lowers cholesterol levels in patients

DIEP, the 'gold standard' of breast reconstruction, is under threat

UnitedHealth’s Q3 profit jumps as medical costs rise more slowly

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Ransomware attacks on hospitals: Study outlines patient impact

Apple is now the first public company to be valued at $3 trillion

How doctors and nurses shape Google's AI

knowledge

How clinical AI models' predictive power can degrade over time

David Sabatini, ex

Astellas still sees hope in its gene therapy after four deaths

Gain of function research would be limited under House proposal

Medicare to cover more brain scans related to Alzheimer’s drugs

What's changing in Medicare's open enrollment this year?

focus

focus

entertainment

leisure time